RxDoctor Payments DataLook up a doctor →

Thomas McKelvey, MD

Internal Medicine · Mobile, ALNPI 1306844394

Payments from drug & device makers

$364,592in general payments, 2019–2025

Across 1,663 payments — averaging $219.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$279K
  • AstraZeneca$41K
  • Johnson & Johnson$22K
  • Bayer$9K
  • Amgen$2K
  • Boston Scientific$2K
  • plus $10K from 40 others

What the payments were for

  • Consulting fees$3,4641%
  • Speaking & faculty fees$316,11987%
  • Travel & lodging$14,8784%
  • Food & beverage$29,6108%
  • Education$5210%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$364,592 in reported general payments places this provider in the 95th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$81,523
Medicare patients
321
Services billed
1,902

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide619$1,139,035
MounjaroTirzepatide434$521,477
FarxigaDapagliflozin Propanediol430$504,742
JardianceEmpagliflozin299$366,715
Repatha SureclickEvolocumab119$131,271
JanuviaSitagliptin Phosphate79$90,811
XareltoRivaroxaban66$67,706
Tresiba Flextouch U-200Insulin Degludec74$63,846
EntrestoSacubitril/Valsartan45$55,869
TrulicityDulaglutide42$53,234
Xigduo XrDapaglifloz Propaned/Metformin37$50,521
LinzessLinaclotide38$42,123
EliquisApixaban37$41,772
MyrbetriqMirabegron37$39,759
Synjardy XrEmpagliflozin/Metformin Hcl27$38,853

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Wegovy$279,483$1,195,323665 claims
Lilly USA, LLCMounjaro, Trulicity$1,102$574,711476 claims
AstraZenecaFarxiga$40,518$504,742430 claims
Boehringer IngelheimJardiance, Synjardy Xr$1,091$405,568326 claims
MerckJanuvia, Janumet Xr$421$112,47397 claims
Johnson & JohnsonXarelto, Invokana$21,833$87,95878 claims
NovartisEntresto$465$55,86945 claims
AbbVieLinzess, Ubrelvy$1,428$53,29150 claims
GSKTrelegy Ellipta, Breo Ellipta$507$41,78469 claims
PfizerEliquis$441$41,77237 claims
Astellas Pharma US IncMyrbetriq$190$39,75937 claims
BayerKerendia$9,077$35,95734 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →